Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Longeveron Inc (NQ: LGVN ) 2.190 -0.020 (-0.90%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 18, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Longeveron Inc < Previous 1 2 ... 9 10 11 12 13 14 15 16 Next > EXCLUSIVE: Longeveron Announces Biomarker Analysis Data From Mid-Stage Study Of Anti-Aging Cell Therapy Candidate September 29, 2021 Longeveron Inc. (NASDAQ: LGVN) announced Wednesday positive biomarker analysis data from the mid-stage study of its lead cell therapy candidate in aging frailty subjects. What... Via Benzinga LONGEVERON ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Longeveron Inc. and Encourages Investors to Contact the Firm September 17, 2021 From Bragar Eagel & Squire, P.C. Via Business Wire SHAREHOLDER ALERT: Robbins LLP Announces that Longeveron Inc. (LGVN) is Being Sued for Misleading Shareholders September 17, 2021 From Robbins LLP Via Business Wire The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline August 18, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV)... Via Benzinga Exposures Product Safety The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business August 17, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16) Bio-Rad Laboratories, Inc... Via Benzinga Heart Hope: Announcing the Encouraging Results of a Cell-Therapy Clinical Study by Longeveron September 15, 2021 Photo by jesse orrico on Unsplash Researchers in the medical field are constantly working to create medicines to prevent and cure diseases. The development of the multiple COVID-... Via Benzinga SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Longeveron Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm September 15, 2021 From The Schall Law Firm Via Business Wire SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Longeveron Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm September 14, 2021 From The Schall Law Firm Via Business Wire EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Longeveron Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – LGVN September 14, 2021 From Rosen Law Firm Via Business Wire Longeveron Announces Final Results of Phase 1 Clinical Study of Lomecel-B Injection in Hypoplastic Left Heart Syndrome Patients September 09, 2021 --Study meets primary safety endpoint: no major adverse cardiac events (MACE), nor any treatment-related infections during the first month post-treatment. --Secondary... Via Benzinga 12 Health Care Stocks Moving In Thursday's Pre-Market Session September 09, 2021 Gainers Soligenix (NASDAQ:SNGX) stock increased by 22.85% to $1.29 during Thursday's pre-market session. The company's market cap stands at $51.7 million. Cardiff... Via Benzinga EXCLUSIVE: Longeveron's Lomecel-B Cell Therapy Meets Primary Safety Endpoint In Phase 1 Rare Congenital Heart Disease Study September 09, 2021 Longeveron Inc. (NASDAQ: LGVN), a cell therapy company developing therapies for age-related and life-threatening conditions, reported Thursday final results from a Phase 1 study... Via Benzinga NASDAQ:LGVN Investor Notice: Investigation over Possible Securities Laws Violations by Longeveron Inc. September 02, 2021 San Diego, CA -- (SBWIRE) -- 09/02/2021 -- Longeveron Inc is under investigation over potential securities laws violations in connection with certain financial statements. Via SBWire The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal August 24, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 23) AbbVie Inc. (NYSE: ABBV) (... Via Benzinga Exposures Product Safety 38 Stocks Moving In Monday's Mid-Day Session August 16, 2021 Gainers NanoVibronix, Inc. (NASDAQ: NAOV) shares climbed 34.5% to $3.3900 after the company announced plan to expand product portfolio with introduction of Painshield relief for... Via Benzinga 60 Biggest Movers From Yesterday August 17, 2021 Gainers NanoVibronix, Inc. (NASDAQ: NAOV) shares jumped 33.7% to close at $3.37 on Monday after the company announced plan to expand product portfolio with introduction of... Via Benzinga 24 Stocks Moving in Monday's Pre-Market Session August 16, 2021 Gainers Enlivex Therapeutics Ltd. (NASDAQ: ENLV) shares rose 26.6% to $12.87 in pre-market trading after the company disclosed that after reviewing its earlier-reported Phase II... Via Benzinga Stocks That Hit 52-Week Lows On Monday August 16, 2021 On Monday morning, 207 companies hit new 52-week lows. Intriguing Points: The largest company in terms of market cap to set a new 52-week low was Koninklijke Philips (NYSE... Via Benzinga 78 Biggest Movers From Friday August 16, 2021 Gainers PharmaCyte Biotech, Inc. (NASDAQ: PMCB) shares jumped 43.4% to close at $3.27. PharmaCyte Biotech recently reported closing of $15-million public offering. Flora Growth... Via Benzinga 12 Health Care Stocks Moving In Friday's Intraday Session August 13, 2021 Gainers Biolase (NASDAQ:BIOL) stock increased by 38.01% to $0.87 during Friday's regular session. Trading volume for this security as of 12:35 EST is 80.8 million,... Via Benzinga 53 Stocks Moving In Friday's Mid-Day Session August 13, 2021 Gainers BIOLASE, Inc. (NASDAQ: BIOL) shares climbed 30.9% to $0.8270 after the company reported better-than-expected Q2 sales. The company said it continues to experience demand... Via Benzinga How Aging-Related Conditions Are Increasing The Treatment Burden For Older Patients August 13, 2021 Via FinancialNewsMedia Stocks That Hit 52-Week Lows On Friday August 13, 2021 Friday morning, 94 companies reached new 52-week lows. Significant Points: Wix.com (NASDAQ:WIX) is the largest company in terms of market cap to set a new 52-week... Via Benzinga EXCLUSIVE: Longeveron Spikes As Lead Drug Produces Dose-Dependent Response In Aging Frailty Study; Primary Endpoint Not Met August 13, 2021 Florida-based biopharma Longeveron Inc. (NASDAQ: LGVN), which is engaged in the development of cell therapies for chronic age-related and life-threatening conditions, announced... Via Benzinga Earnings Scheduled For August 13, 2021 August 13, 2021 Companies Reporting Before The Bell • Jaguar Health (NASDAQ:JAGX) is expected to report quarterly loss at $0.03 per share on revenue of $7.28 million. • Fangdd... Via Benzinga The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More July 25, 2021 Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start... Via Benzinga Exposures Product Safety Longeveron's Founders Hopeful That With Continued Clinical Trial Success, Lomecel-B May Win Regulatory Approval July 07, 2021 Longeveron Inc. (NASDAQ: LGVN) is optimistic it could receive regulatory approvals in different countries for its lead regenerative medicine product Lomecel-B (cell-based... Via Benzinga Longeveron, Armed with Positive Results of Phase I Clinical Study of Lomecel-B Cell Therapy for Alzheimer's Disease, Presenting at AAIC & Headed to Phase 2 Trials June 28, 2021 Longeveron CEO Geoff Green presented at the Benzinga Global Small Cap Conference held on May 13-14, 2021. In addition to sharing the company’s corporate outlook, Green... Via Benzinga Alzheimer’s Treatment Market Is Anticipated To Reach $2 Billion By The End Of 2027 June 24, 2021 Via FinancialNewsMedia Topics Death Exposures Death Longeveron Announces Abstract Highlighting Data from Phase 1 Alzheimer's Disease Trial Accepted for Developing Topics Presentation at the 2021 Annual Alzheimer's Association International Conference June 24, 2021 - Abstract presentation highlights safety and potential efficacy of Lomecel-B infusion in patients with mild Alzheimer’s Disease - Miami, Florida – June 24th, 2021 -... Via Benzinga < Previous 1 2 ... 9 10 11 12 13 14 15 16 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.